Advertisement
A vs TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- A has posted stronger recent momentum, with double-digit gains over the past month and roughly 26% over the past three months, supported by accelerated organic growth.
- TMO is the larger, more diversified life sciences tools franchise, with annual revenue above $45 billion versus roughly $7.5 billion for A.
- A delivered 7.3% core revenue growth in its most recent quarter, led by pharma, China, and advanced therapeutics, while TMO posted 1% organic growth in its latest reported quarter.
- Both names are benefiting from recovering pharma and biotech spending, but their market positioning, growth profiles, and risk factors differ meaningfully.
- TMO trades at a higher earnings multiple and carries more execution-driven portfolio activity, including acquisitions and divestitures.
- Relative performance favors A in the current environment, though TMO offers greater scale and diversification.
Introduction
Investors evaluating the life sciences and laboratory tools sector often weigh A (Agilent Technologies) against TMO (Thermo Fisher Scientific). Both companies supply analytical instruments, laboratory products, and services to pharmaceutical, biotech, diagnostics, and applied markets, yet they operate at very different scales and with distinct growth drivers. This stock comparison examines how the two names have performed in recent market activity, what has shaped their relative performance, and where each stands in terms of momentum, stability, and market positioning. The analysis is relevant for both growth-oriented traders tracking short-term trends and long-term investors assessing sector exposure.
A Overview and Recent Performance
Agilent Technologies (A) provides application-focused solutions across life sciences, diagnostics, and applied chemical markets, with a product portfolio spanning liquid and gas chromatography, mass spectrometry, and pathology instruments. In its most recent fiscal quarter, the company reported revenue of approximately $1.88 billion, with core revenue growth of 7.3% that exceeded the top end of guidance, alongside non-GAAP earnings per share (EPS) growth of roughly 18% year over year.
Recent momentum has been notably strong. The stock has advanced by double digits over the past month and roughly 26% over the past three months, reflecting improving end-market conditions. Key contributors include 12% pharma growth, nearly 30% growth in advanced therapeutics, and a 9% increase in China. Management has also cited a book-to-bill ratio above one for ten consecutive quarters, signaling healthy order momentum. Product launches, including new chromatography and mass spectrometry platforms, and early pharma reshoring orders have reinforced sentiment, prompting several analysts to upgrade the stock in recent weeks.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO) is the world's largest life sciences tools and services provider, generating annual revenue above $45 billion across life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. In its latest reported quarter, revenue grew 6% to $11.01 billion, with adjusted EPS up 6% to $5.44, while organic revenue growth was a more modest 1%.
Over the past three months, TMO has also rallied, gaining roughly 26% over that period, with a one-year total shareholder return near 24%. Sentiment has been supported by improving pharma and biotech funding, a strategic collaboration with NVIDIA on AI-driven laboratory instrumentation, and the completed acquisition of Clario, an endpoint data solutions provider. The company is also divesting its microbiology business for approximately $1.075 billion as part of active portfolio management. Analysts have lifted price targets into the $700 to $760 range in recent weeks, maintaining a broadly constructive view.
Trending AI Robots
For traders seeking a data-driven edge in the current market, Tickeron's Trending AI Robots page offers a curated view of the platform's AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and statistics. Because conditions shift frequently, only the best-performing and most suitable bots for the present environment earn a place in this curated section, helping users identify strategies that are currently resonating. Whether you favor short-term momentum or longer-horizon positioning, the page provides a practical starting point for exploring automated approaches to names like A and TMO. Explore the Trending AI Robots selection to see which strategies are leading right now.
Head-to-Head Comparison
The clearest contrast between these two stocks is scale and diversification. TMO operates a far broader portfolio, including a major pharmaceutical services (CDMO) business through Patheon and PPD, giving it deeper exposure to drug manufacturing and clinical research. A is more focused on analytical instrumentation and diagnostics, which can make it more sensitive to instrument replacement cycles and capital spending trends.
On growth, A has recently delivered faster organic expansion, with 7.3% core growth versus 1% organic growth for TMO in its latest quarter. On valuation, TMO trades at a higher price-to-earnings (P/E) multiple, reflecting its scale and defensive qualities. Risk profiles also differ: A carries meaningful exposure to China and to the pace of instrument replacement cycles, while TMO faces execution risk around its active M&A (mergers and acquisitions) and divestiture activity, as well as a lower-margin services mix.
Tickeron AI Verdict
Based on observable trend consistency, relative performance, and near-term catalysts, Tickeron's AI would likely lean toward A in the current environment. The stock's stronger organic growth, ten consecutive quarters of book-to-bill above one, and clear momentum in pharma, China, and advanced therapeutics suggest a more consistent and accelerating trend profile. TMO remains the more stable, diversified franchise, but its lower organic growth rate and ongoing portfolio reshuffling introduce more execution variability in the near term. These signals point probabilistically toward A as the current AI-favored candidate, though both names retain fundamentally sound positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and TMO is a Hold.
Aroon Indicator for A shows an upward move is likely
A's Aroon Indicator triggered a bullish signal on October 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 141 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 186 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 20 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 70 cases where A's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on A as a result. In 58 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.505) is normal, around the industry mean (63.909). P/E Ratio (33.379) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
TMO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TMO turned positive on October 16, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TMO as a result. In 54 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 196 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 145 of 246 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 20 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 21 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.768) is normal, around the industry mean (63.909). P/E Ratio (36.506) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
A | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 94 | 77 | |
SMR RATING 1..100 | 45 | 60 | |
PRICE GROWTH RATING 1..100 | 14 | 21 | |
P/E GROWTH RATING 1..100 | 35 | 22 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for TMO (68) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (77) in the Medical Specialties industry is in the same range as A (94) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as TMO (60) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
A's Price Growth Rating (14) in the Biotechnology industry is in the same range as TMO (21) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (22) in the Medical Specialties industry is in the same range as A (35) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
| A | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 53% |
| Stochastic ODDS (%) | 1 day ago 63% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 59% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 62% |
| Advances ODDS (%) | 5 days ago 62% | 5 days ago 63% |
| Declines ODDS (%) | 1 day ago 63% | 1 day ago 62% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 65% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 2 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 2 bullish, 6 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -0.83% price change this week, while TMO (@Medical Specialties) price change was +2.59% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.01%. For the same industry, the average monthly price growth was -7.30%, and the average quarterly price growth was +34.04%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
TMO is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Medical Specialties (-4.01% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | -1.54% | ||
| A - TMO | 74% Closely correlated | -1.77% | ||
| DHR - TMO | 71% Closely correlated | -2.01% | ||
| RVTY - TMO | 69% Closely correlated | -1.11% | ||
| IQV - TMO | 68% Closely correlated | -0.38% | ||
| BRKR - TMO | 67% Closely correlated | +1.04% | ||
More | ||||